Login & Signup

  • PreIPO
  • Startup Fund Raising
  • Valuations
  • Equity Restructing

  • Investments
  • Mutual Funds
  • Demat Account
  • Bonds/NCD
  • Insurance
  • Life Insurance
  • Health Insurance
  • Car Insurance
  • Corporates & Business
  • Property Insurance
  • Group Health Insurance
  • Marine Insurance
S

RATING

RECOMMENDATION

Buy

  • Portfolio

  • Basket

  • Watchlist

  • More

RATING

RECOMMENDATION

Buy

Business Type

Fairly Valued

  • unlisted stock logo
    East India Pharmaceutical Works Limited Unlisted Shares Essentials

ISIN

INE254X01017

Face Value

₹10.00

Total Share

66,74,858

Total Income

₹17,269.64 L

Profit After Tax

₹314.85 L

Promoter Holding

69.90 %

EPS

₹4.72

P/E

16.53

P/B

0.02

Market Capitalisation

₹52.06 Cr

Book Value

₹4,691.87 L

Intrinsic Value

₹96.76

Sector

Health Care

Sub-sector

Pharmaceuticals

Cashflow - Operations

₹759.35 L

Cashflow - Financing

-₹395.98 L

East India Pharmaceutical Works Limited Growth

Compounded Sales Growth

  • 8.92%

    1 Year

  • 4.41%

    3 Year

  • 3.54%

    4 Year

Pro Only

Compounded Profit Growth

  • 56.88%

    1 Year

  • 66.56%

    3 Year

  • 13.47%

    4 Year

Pro Only

Return On Equity

  • 6.71%

    1 Year

  • 2.92%

    3 Year

  • 1.60%

    4 Year

Pro Only

About East India Pharmaceutical Works Limited

Overview: 

  • On April 27, 1936, East India Pharmaceutical Works Limited, one of the oldest pharmaceutical companies in India, was born.
  • Depending solely on national resources and talents – East India Pharmaceutical Works Limited (EIPWL) now has emerged as a large pharmaceutical company with two manufacturing units, workforce of 1400 employees and an annual turnover of around Rs.1300 million.
  • Quality is the hallmark of EIPWL. At every stage of production, from raw materials to finished products, highest standard of quality is ensured with the help of most modern equipment, trained personnel and the state-of-the art R&D Department.
  • Headquartered in Kolkata, EIPW is one of the oldest pharmaceutical companies in India. Our years of experience and a focused ‘people-centric approach’ have empowered us to evolve with the changing healthcare needs and offer high-quality advanced medicines for modern-day health complexities.

  • East India Pharmaceutical Works Limited Subsidiaries

Qasar Healthcare Private Limited
  • East India Pharmaceutical Works Limited Product & Services

Therapies

Analgesic- Antipyretic

Antibiotic

Antiprotozoal

Antivirus

Cough Syrup

Decongestant

Digestive Aid

Haematinic 

Injectable

Ophthalmic

Probiotic

Vitamins

Herbals

Cough Syrup

Gynaecologist

Hepatoprotective

Metabolic

Urological


  • East India Pharmaceutical Works Limited Industry Overview

Industry Statistics

Introduction: 

  • Healthcare has become one of India’s largest Sector, both in terms of revenue and employment.
  • Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance and medical equipment.
  • The Indian healthcare sector is growing at a brisk pace due to its strengthening coverage, services and increasing expenditure by public as well private players.
  • India's competitive advantage lies in its large pool of well-trained medical professionals. 
  • India is also cost competitive compared to its peers in Asia and Western countries. The cost of surgery in India is about one-tenth of that in the US or Western Europe.

Market size: 
  • The healthcare market can increase three-fold to Rs. 8.6 trillion (US$ 133.44 billion) by 2022. In Budget 2021, India’s public expenditure on healthcare stood at 1.2% as a percentage of the GDP.
  • A growing middle-class, coupled with rising burden of new diseases, are boosting the demand for health insurance coverage. 
  • With increasing demand for affordable and quality healthcare, penetration of health insurance is poised to expand in the coming years. In FY21, gross written premiums in the health segment grew at 13.7% YoY to Rs. 58,584.36 crore (US$ 8.00 billion).
  • The health segment has a 29.5% share in the total gross written premiums earned in the country.

Future Prospects

  • Between April 2000 and December 2020, FDI inflows for drugs and pharmaceuticals sector stood at US$ 17.74 billion
  • In February 2021, India approved the commercial supply of 24 million doses of COVID-19 vaccines to 25 countries, more than 2x the 10.5 million vaccines exported in January 2021. Through this, seven countries, including Brazil, Morocco and South Africa, were sent >~10 million doses on a commercial basis.
  • By March 2021, India exported more vaccines than it had administered to its citizens—60 million doses had been dispatched to 76 countries, while 52 million doses had been administered to Indian citizens. Apart from vaccines, drugs indicated for Covid-19 treatment too witnessed an uptrend in exports. For example, Remdesivir exports doubled in March 2021 to $14.8 million from $5.75 million in February 2021
  • In February 2021, Prime Minister Narendra Modi laid the foundation stones for two hospitals and launched ‘Asom Mala’, a programme for state highways and major district roads, in Assam. He also added that ~1.25 crore people in the state are being benefitted from Ayushman Bharat Scheme.

Government Initiatives

  • On May 12, 2021, the Drugs Controller General of India (DCGI), accepted recommendation of Subject Expert Committee (SEC) and accorded permission to conduct the Phase II/III clinical trials of Covaxin (COVID vaccine) for the age group of 2-18 years to its manufacturer, Bharat Biotech Ltd.
  • On May 17, 2021, the Defence Ministry launched the first batch of anti-COVID drug, 2-deoxy-D-glucose (2-DG) that was developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), along with Dr. Reddy’s Laboratories (DRL), Hyderabad.
  • In May 2021, the government announced its plan to ramp up supply and availability of Amphotericin-B, the anti-fungal drug, for treatment of the ‘Black Fungus’ disease. It has also given the license to five manufactures to produce the drug within the country.

East India Pharmaceutical Works Limited Strengths

  • Profit for the year of the Company has been increased from INR 200.69 Lakhs in FY 2020 to INR 314.85 Lakhs in FY 2021 showcased a growth of 56.88%.
  • Quality has been the hallmark of EIPW. Our well-experienced medical and research team, supported by the most advanced and precise equipment and infrastructure, ensure international standard quality at every stage of production.

East India Pharmaceutical Works Limited Shortcomings

Company’s Solvency Ratio is quite decent at its own, but in comparison to peers it’s a little low that needs to be improvement. 

East India Pharmaceutical Works Limited Opportunities

Healthcare market in India is expected to reach USS 193.83 billion by 2020 and USS 372 billion by 2022, driven by rising income, better health awareness, lifestyle diseases and increasing access to insurance.


The Government of India aims to increase healthcare spending to 3% of the Gross Domestic Product (GDP) by 2022.



East India Pharmaceutical Works Limited Threats

The healthcare landscape continues to evolve, with regulatory changes and scrutiny on the rise. This trend continues due to pressure to reduce regulation and control regulatory costs.

East India Pharmaceutical Works Limited Rating

  • RECOMMENDATION

    Buy

  • East India Pharmaceutical Works Limited Detail Info

Industry Statistics

PUBLIC LIMITED

Registered In

India

last Updated

12/09/2021

Registered Date

27/04/1936

Planify Ticker

esdsd

Reg Office: 6, Nandalal Bose Sarani, Kolkata 700 071

Website: http://www.eastindiapharma.org